Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma
Status:
Recruiting
Trial end date:
2024-04-01
Target enrollment:
Participant gender:
Summary
This study evaluates the safety and efficacy of novel BCMA-targeted CAR-T cell therapy
(CBG-002) for patients with relapsed or refractory multiple myeloma (r/r MM). CBG-002 is
designed based on the fourth-generation of CAR-T techonology.
Phase:
Phase 1
Details
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University